Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 70,629 shares, a growth of 69.3% from the July 15th total of 41,707 shares. Based on an average daily volume of 401,906 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company’s shares are short sold.
Astellas Pharma Trading Up 0.6%
Shares of ALPMY stock opened at $14.42 on Wednesday. The stock has a market capitalization of $26.10 billion, a PE ratio of 10.97 and a beta of 0.08. Astellas Pharma has a 1-year low of $10.03 and a 1-year high of $17.35. The business has a 50-day moving average of $13.62 and a 200 day moving average of $14.66. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.17 and a quick ratio of 0.90.
Analysts Set New Price Targets
Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.
Astellas Pharma Company Profile
Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).
See Also
- Five stocks we like better than Astellas Pharma
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
